Current stock page

Financial Data

PTGX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

PTGXProtagonist Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$130.95−$3.43 (−2.55%)

Latest quote

  • Momentum
    70
  • Value
    72
  • Quality
    81
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$274.41M$213.48M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M
Gross Profit$273.31M$213.48M$55.96M$7.44M$4.71M$5.55M$28.32M$170.64M
Operating Income$218.33M$158.77M-$3.65M-$50.36M-$46.42M-$42.04M-$19.31M$126.78M
Net Income$220.02M$162.85M$3.78M-$44.38M-$39.34M-$34.77M-$11.66M$131.67M
EPS$3.32$2.47$0.06-$0.69-$0.62-$0.55-$0.19$2.11
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$23.22M$219.05M-$48.94M-$36.98M-$1.94M-$28.78M$125.36M-$29.18M
Capital Expenditure-$237K-$168K-$215K-$144K-$88K-$813K-$545K-$310K
Free Cash Flow-$23.46M$218.88M-$49.16M-$37.12M-$2.03M-$29.59M$124.82M-$29.49M
Net Cash Provided By Operating Activities-$23.22M$219.05M-$48.94M-$36.98M-$1.94M-$28.78M$125.36M-$29.18M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.15B$885.54M$697.46M$669.89M$701.69M$718.01M$742.13M$744.73M
Total Debt$8.63M$9.22M$9.78M$10.32M$10.75M$11.28M$11.36M$10.87M
Cash And Cash Equivalents$498.3M$420.08M$193.71M$128.39M$113.71M$168.54M$139.65M$97.25M
Total Liabilities$61.64M$44M$41.99M$55.19M$56.25M$49.99M$53.08M$69.43M
Total Stockholders Equity$1.08B$841.54M$655.47M$614.71M$645.44M$668.02M$689.05M$675.3M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio27.67117.61——110.8265.7447.079.35
P/B ratio8.7311.5910.679.017.885.123.843.81
P/S ratio15.75———————
Debt To Equity0.010.010.010.020.020.020.020.02
Free Cash Flow Yield1.17%1.36%-1.66%1.04%1.25%1.08%12.68%7.10%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio27.67117.61——110.8265.7447.079.35
P/B ratio8.7311.5910.679.017.885.123.843.81
P/S ratio15.75———————
Return On Equity31.55%9.85%-17.50%-21.17%7.11%7.79%8.16%40.75%
Debt To Equity0.010.010.010.020.020.020.020.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe25.39x
Pb8.01x
Revenue Growth Yoy5723.64%
EPS Growth Yoy635.48%
Gross Margin99.73%
Operating Margin58.56%
ROE42.83%
ROIC28.87%
Debt To Equity0.01
FCF Yield1.28%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$130.95
Volume759,916
RSI (14)38.86
MACD-1.83
MACD signal-1.1
MACD histogram-0.73
ADX (14)19.72
SMA (50)$140.30
SMA (200)$119.29
ATR (14)$5.90
Historical volatility (annualized)37.65%
Volume (20-day average)607,781

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score70/100
Beta0.91
Annual volatility40.11%
Max Drawdown-18.83%
Sharpe Ratio1.24
VaR (95%, 1-day)-3.69%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PTGX Financial Data FAQ

What is Protagonist Therapeutics, Inc.'s revenue?

Protagonist Therapeutics, Inc.'s revenue is one of the core financial data points for PTGX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Protagonist Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Protagonist Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PTGX's EPS?

PTGX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Protagonist Therapeutics, Inc.'s net income?

Protagonist Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Protagonist Therapeutics, Inc. generate?

Free cash flow shows how much cash Protagonist Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Protagonist Therapeutics, Inc. have?

Cash and debt help frame PTGX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.